Kutatási jelek – Signal Engine

• Frontiers | Case Report: Two cases of pathologic complete response after upfront chemoimmunotherapy for initially unresectable gastric cancer — Gastric cancer
• Fulminant pheochromocytoma crisis triggered by glucocorticoids: ultra‑early adrenalectomy under ECMELLA support — Esophageal cancer
• Sociodemographic and clinical predictors of malignancy in thyroid nodules: a systematic review and meta-analysis — Thyroid cancer
• Blocking cellular 'freecycling' may slow bone marrow scarring in myelofibrosis — Myelofibrosis
• Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapies — Adenoid cystic carcinoma
• Revisiting prognostic biomarkers in gastrointestinal stromal tumor: the potential role of ETV1 polymorphisms — Gastrointestinal stromal tumor
• Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma — NSCLC
• MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms — Acute myeloid leukemia
• Zanubrutinib Induced Acneiform Rash in a Patient With Waldenstrom ’s Macroglobulinemia — Waldenstrom macroglobulinemia
• Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence — Diffuse large B-cell lymphoma
• Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. — NSCLC
• IL7-ReceptorTargeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia — Acute lymphoblastic leukemia
• Case Report: Lorlatinib for the treatment of ALK‑rearranged poorly differentiated thyroid carcinoma after progression to prior ALK‑specific tyrosine‑kinase inhibitor — Thyroid cancer
• High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights — Chronic lymphocytic leukemia
• Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer. — Head and neck squamous cell carcinoma
• Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial — Nasopharyngeal carcinoma
• The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights — Osteosarcoma
• Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial — Cholangiocarcinoma
• Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma — Multiple myeloma
• Tumor heterogeneity: development, mechanisms, and therapeutic implications — Acute myeloid leukemia